Share Email Print
cover

Proceedings Paper

Trehalose as a cryoprotective agent for use during prostate cryoablation
Author(s): T. Schroeder; S. Roychowdhury; E. Koullick
Format Member Price Non-Member Price
PDF $14.40 $18.00
cover GOOD NEWS! Your organization subscribes to the SPIE Digital Library. You may be able to download this paper for free. Check Access

Paper Abstract

Cryoablation is a prostate cancer treatment which uses extreme cold to kill prostate cancer cells. Unfortunately, cryoablation is not specific to cancer cells and normal cells within and surrounding the ice ball may also die which often includes those in the neurovascular bundles (NVBs). The NVBs contain neuronal and vascular components essential for erectile function and continence, and damage can cause impotence and incontinence. Therefore, agents that protect the NVBs during cryoablative procedures are extremely important for the next generation of this technology. The purpose of these studies was to analyze various agents for their ability to reduce cellular toxicity upon freezing of fibroblasts and neuronal cells. The agents were compared against DMSO, a well accepted but toxic cryoprotective agent (CPA). Various concentrations of trehalose, PVP, PEG, and DMSO were incubated with fibroblast or neuronal cells for 45 minutes at 37°C, frozen in liquid nitrogen for one hour, thawed in a 37°C water bath for 5 minutes, and then plated in 6 well plates. After 18 hours, live cells were counted using the trypan blue exclusion assay. No cells survived in DMEM alone, however, cell viability was observed in the trehalose and DMSO treated samples in both cell types and in the fibroblast cells only for PEG treated samples. To mimic the general cryoablation procedure consisting of 2 freeze/thaw cycles, neuronal cells were frozen and thawed twice. Cell viability was observed in the some trehalose and DMSO treated cells. Our experiments demonstrate that trehalose is capable of acting as a CPA of both fibroblasts and nerve cells. Its overall ability to act as a CPA is comparable to DMSO, a widely used and well accepted CPA, thus warranting further experimentation with this agent.

Paper Details

Date Published: 8 February 2008
PDF: 8 pages
Proc. SPIE 6842, Photonic Therapeutics and Diagnostics IV, 68420U (8 February 2008); doi: 10.1117/12.763368
Show Author Affiliations
T. Schroeder, American Medical Systems Inc. (United States)
S. Roychowdhury, American Medical Systems Inc. (United States)
E. Koullick, American Medical Systems Inc. (United States)


Published in SPIE Proceedings Vol. 6842:
Photonic Therapeutics and Diagnostics IV
Kenton W. Gregory; Guillermo J. Tearney; Reza S. Malek; Nikiforos Kollias; Bernard Choi; Haishan Zeng; Brian Jet-Fei Wong; Justus F. R. Ilgner; Henry Hirschberg; Steen J. Madsen, Editor(s)

© SPIE. Terms of Use
Back to Top